Related Experiment Video
Updated: Feb 12, 2026
07:49
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
2.0K
Next-generation small molecule therapies for heart failure: 2015 and beyond
Justin T Malinowski1, David J St Jean1
1Amgen Discovery Research, 360 Binney St., Cambridge, MA 02142, USA.
Bioorganic & Medicinal Chemistry Letters
|April 5, 2018
Summary
Heart failure (HF) presents a major global health challenge. This review covers recent HF treatments and emerging small molecule therapies in development.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Heart failure (HF) is a significant global health issue with poor prognosis and high economic impact.
- Despite advances, only two new HF-specific medications have been approved since 2007, highlighting a need for novel treatments.
Purpose of the Study:
- To provide an overview of recently approved heart failure (HF) treatment options.
- To update on small molecule therapies for HF currently undergoing clinical development.
Main Methods:
- Literature review of recent HF treatment approvals.
- Survey of ongoing clinical trials for small molecule HF therapies.
Main Results:
- Limited number of new HF-specific medications approved in recent years.
- Several small molecule therapies are in various stages of clinical development for HF.
Conclusions:
- There is an ongoing need for innovative therapeutic strategies to address the challenges posed by heart failure (HF).
- Emerging small molecule therapies show promise for future HF treatment paradigms.
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
395
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
395
01:29Heart Failure II: Pathophysiology
1.0K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
01:17Pathophysiology of Heart Failure
4.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
01:27Heart Failure I: Introduction
951
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
951
01:22Heart Failure Drugs: Diuretics
1.0K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K
01:30Heart Failure V: Medical Management
360
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
360